Piramal Pharma Ltd. Company History and Annual Growth Details

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.

Major events and milestones:

2020

-Acquired pharmaceutical business from PEL

-20% Strategic Growth Investment by Carlyle

-Increased stake to 100% in CCPL

2021

Acquisition of HPPL

2022

-Acquisition of minority stake in Yapan Bio Private Limited

-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company.

2020
-Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals.
-Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs.
-Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish
-Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare

2021
-Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity.
-Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.
-Piramal Pharma LimitedÂs Consumer Products Division Launches Âi-feelÂ®Â

2022
-Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity.
-Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND.
-Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site.
-Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed.

2023

-Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

2024

- Piramal Pharma Limited (PPL) launches new campaign for Polycrol with Brand Ambassador Jisshu Sengupta.

-Piramal Pharma Limited ( the Company ) forays into men's grooming market with the launch of BOHEM.

2025

-Piramal Critical Care Announces U.S. Launch of ChlorpromazineHydrochloride for Injection, USP.

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article